Skip To Main Content
Tatyanah Farsh on Muck Rack

Tatyanah Farsh

As seen in: Nature, The Journal of Clinical Investigation
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Tatyanah

Contact Tatyanah, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer - Nature Genetics

|
By Haolong Li, Raunak Shrestha, Meng Zhang, Martin Sjöström, Jasmine Anderson, Tatyanah Farsh, Seema Nath, Jonathan Chou, Ashutosh Maheshwari, Mohammed Alshalalfa, Arun P. Wiita, Bo Huang, Eric Small, Peter Nelson, David Quigley Verified, Luke A Gilbert
| Nature Verified
Abstract The androgen receptor (AR) is a critical driver of prostate cancer (PCa). Here, to study regulators of AR protein levels and oncogenic activity, we developed a live-cell quantitative endogenous AR fluorescent reporter. Leveraging this AR reporter, we performed genome-scale CRISPRi flow cytometry sorting screens to systematically identify genes that modulate AR protein levels.
Open in Who Shared Issue with article?

Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer

|
By Xiaolin Zhu, Tatyanah Farsh, Daniel C Vis, Ivan Yu, Daniel J Vis, Haolong Li, Tianyi Liu, Martin Sjöström, Raunak Shrestha, Jeroen Kneppers, Tesa M. Severson, Meng Zhang, Arian Lundberg, Alana Weinstein, Adam Foye, Niven Mehra, Rahul Aggarwal, Thaidy Moreno Rodriguez
| The Journal of Clinical Investigation
Abstract Introduction Metastatic castration-resistant prostate cancer (mCRPC) is the lethal form of prostate cancer (PCa) (1). Androgen receptor signaling inhibitors (ARSIs), such as abiraterone and enzalutamide, have improved outcomes for patients with mCRPC and hormone-sensitive prostate cancer (HSPC) (1). However, PCa invariably develops resistance to ARSIs, leaving patients with limited treatment options following disease progression (2).
Open in Who Shared Issue with article?
See all 2 articles